Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Amyloidosis, Hereditary Clinical Trial

Official title:

Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy

Clinical Trial Details — Status: Approved for marketing

Administrative data

• NCT number: NCT02939820
• Other study ID #: ALN-TTR02-007
• Status: Approved for marketing

Study information

• Verified date: May 2024
• Source: Alnylam Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).

Description:

Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the links provided in More Information.

Recruitment information / eligibility

• Status: Approved for marketing
• Enrollment: 0
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female greater than or equal to 18 years of age

• Have a diagnosis of hATTR

• Meet Karnofsky performance status and Polyneuropathy Disability (PND) score requirements

• Have adequate complete blood counts, liver function tests and coagulation tests

Exclusion Criteria:

• Participated in an interventional hATTR amyloidosis clinical trial involving RNA interference (RNAi) therapeutics within the last 12 months

• Are currently eligible to participate in or currently enrolled in an ongoing interventional hATTR amyloidosis clinical trial

• Have inadequate cardiac function

• Known primary amyloidosis (AL amyloidosis) or leptomeningeal amyloidosis

• Have known serious comorbidities or considered unfit for the program by the investigator

• Prior or planned liver or heart transplantation

Related Conditions & MeSH terms

• Amyloid Neuropathies
• Amyloid Neuropathies, Familial
• Amyloidosis
• Amyloidosis, Familial
• Amyloidosis, Hereditary
• Amyloidosis, Hereditary, Transthyretin-Related
• Familial Amyloid Polyneuropathies
• Polyneuropathies
• TTR-mediated Amyloidosis

Intervention

Drug:
• patisiran (ALN-TTR02)
patisiran (ALN-TTR02) administered by intravenous (IV) infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Alnylam Pharmaceuticals

External Links

•   https://ghr.nlm.nih.gov/condition/transthyretin-amyloidosis
•   https://www.nlm.nih.gov/medlineplus/amyloidosis.html